GANX - Gain therapeutics appoints Evan Ballantyne as chief financial officer
2023-04-12 16:41:55 ET
- Gain Therapeutics ( NASDAQ: GANX ) said it had appointed Evan Ballantyne as the Chief Financial Officer.
- Ballantyne is expected to succeed Salvatore Calabrese's role, and during a reasonable transition period, Calabrese will remain employed by the company to aid in the transition of responsibilities .
For further details see:
Gain therapeutics appoints Evan Ballantyne as chief financial officer